The recent statistics indicate that the Indian pharmaceutical market is currently valued at USD25 billion and is expected to further grow at a CAGR of 12 per cent till 2020. India is the third largest pharmaceutical market in the world by incremental growth and seventh largest by volume, which gives a plethora of opportunities for many life sciences companies. With India’s population expected to reach 1.4 billion in 2022 (as per the 2015 UN Report on World Population), this growing population demands not only large scale production of vaccines but also research for newer vaccines relevant to India and immunotherapy. In order to meet the growing demands of the denizens of the country, Corning Life Sciences, one of the leaders in developing, manufacturing and global supplier of scientific laboratory products for over 100 years, has rolled its sleeves to achieve its goal. Outside of US, India and China are two of the biggest markets for Corning Life Sciences (CLS). In a recent conversation with BioSpectrum, Dr. Richard M. Eglen, Vice President and General Manager, Corning Life Sciences (CLS), and President, Corning International Emerging Market, revealed the expansion plans of CLS and how the company is gearing up to achieve its goal.
How does Corning Life Sciences see the Asian pharmaceutical market as one of the prominent domains to carry out its business operations?
One of the major reasons why we have entered the Asian market is the rapid growth in the pharmaceutical market; that, coupled with the rate at which the population is growing, which is higher than any other continent. This rapid growth in population is creating a great demand for new types of medicines and also allowing us to bring a wide range of our products in this lucrative market. Another reason that brought us here is the booming market; if you compare the growth in Asia to USA’s market, it is almost twice of America.
As we develop new products in life sciences, we felt that these are also perfectly carved to address the needs of the Asian market. Currently, our major focus is on India and we our planning to surge our vaccine production which is in great demand.
Do you consider India as one of your major platform to boost your business?
Diese Geschichte stammt aus der January 2017-Ausgabe von Bio Spectrum.
Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.
Bereits Abonnent ? Anmelden
Diese Geschichte stammt aus der January 2017-Ausgabe von Bio Spectrum.
Starten Sie Ihre 7-tägige kostenlose Testversion von Magzter GOLD, um auf Tausende kuratierte Premium-Storys sowie über 8.000 Zeitschriften und Zeitungen zuzugreifen.
Bereits Abonnent? Anmelden
Sartorius Stedim Biotech opens new centre for bioprocess innovation in US
Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, has opened its new centre for Bioprocess Innovation in Marlborough, Massachusetts in the US.
Agilent introduces innovative Mito-rOCR assay kit for mitochondrial research
Agilent Technologies Inc. has announced the new MitorOCR Assay Kit.
Qiagen launches AI-extension of Ingenuity Pathway Analysis for automatic interpretation of biological data
Qiagen has announced the launch of Ingenuity Pathway Analysis (IPA) Interpret, a new feature designed to simplify and accelerate the interpretation of complex biological data.
Parse Biosciences announces expansion of Evercode BCR product line
Parse Biosciences, a leader in scalable single cell sequencing solutions, has announced the expansion of its Evercode BCR product line to enable applications in mice.
New technology for unambiguous detection of HIV genome using tailored fluorogenic tests
A team of scientists at Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), has developed a novel diagnostic technology known as the GQ Topology-Targeted Reliable Conformational Polymorphism (GQ-RCP) platform.
Gene mutation likely cause for developing autism in early childhood: RGCB study
Autism, a developmental disorder that causes functional abnormalities in brain development, is caused by a combination of environmental and genetic factors with its symptoms manifesting in childhood as early as the age of two years.
IIIT-Delhi unveils AI platform for discovering molecules that promote healthy ageing
A team of researchers from Indraprastha Institute of Information Technology Delhi (IIIT-Delhi) has developed AgeXtend, a groundbreaking artificial intelligence (AI)-based platform that is set to transform the search for molecules promoting healthy ageing.
RSSDI study lays focus on Yoga and Diabetes Prevention
Dr Jitendra Singh, Union Minister of State (Independent Charge) for Science and Technology, recently released the landmark study by Research Society for Study of Diabetes in India (RSSDI) on 'Yoga and Diabetes Prevention'.
Dr Alok Khullar steps in as Group CEO of RJ Corp Healthcare
RJ Corp Healthcare, a leading name in the healthcare sector through its renowned entities Cocoon Hospital and Cryoviva Stem Cell Bank, has announced the appointment of Dr Alok Khullar as Group Chief Executive Officer (CEO).
Entod Pharmaceuticals on-boards Dr Anish Desai as Scientific & Research adviser
Mumbai-based Entod Pharmaceuticals has appointed Dr Anish Desai as its Scientific and Research Adviser.
